Latest Information Update: 22 Feb 2005
At a glance
- Originator Wilex
- Class Antineoplastics
- Mechanism of Action Urokinase-type plasminogen activator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Feb 2005 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 01 May 2003 This compound is still in active development
- 13 Jul 2000 Preclinical development for Cancer in Germany (Unknown route)